

Amyloid Inhibitors

International Edition: DOI: 10.1002/anie.201914559
German Edition: DOI: 10.1002/ange.201914559

Structural Insight into IAPP-Derived Amyloid Inhibitors and Their Mechanism of Action

Zheng Niu, Elke Prade, Eleni Malideli, Kathleen Hille, Alexander Jussupow, Yonatan G. Mideksa, Li-Mei Yan, Chen Qian, Markus Fleisch, Ana C. Messias, Riddhiman Sarkar, Michael Sattler, Don C. Lamb, Matthias J. Feige, Carlo Camilloni, Aphrodite Kapurniotu,* and Bernd Reif*

Abstract: Designed peptides derived from the islet amyloid polypeptide (IAPP) cross-amyloid interaction surface with A β (termed interaction surface mimics or ISMs) have been shown to be highly potent inhibitors of A β amyloid self-assembly. However, the molecular mechanism of their function is not well understood. Using solution-state and solid-state NMR spectroscopy in combination with ensemble-averaged dynamics simulations and other biophysical methods including TEM, fluorescence spectroscopy and microscopy, and DLS, we characterize ISM structural preferences and interactions. We find that the ISM peptide R3-GI is highly dynamic, can adopt a β -like structure, and oligomerizes into colloid-like assemblies in a process that is reminiscent of liquid–liquid phase separation (LLPS). Our results suggest that such assemblies yield multivalent surfaces for interactions with A β 40. Sequestration of substrates into these colloid-like structures provides a mechanistic basis for ISM function and the design of novel potent anti-amyloid molecules.

Introduction

Peptides mimicking the cross-amyloid interaction surface of the type 2 diabetes (T2D) human islet amyloid polypeptide (hIAPP) with the Alzheimer's disease β -amyloid protein

A β 40/42, termed interaction surface mimics (ISMs), have been shown to be nanomolar inhibitors of amyloid self-assembly of A β 40/42.^[1] The molecular mechanism is, however, not well understood. The design of the ISMs was based on the finding that amyloids are generally composed of a β -sheet-turn- β -sheet structural motif and that IAPP uses the same two binding regions for both its amyloid self- and its cross-amyloid hetero-assembly with A β 40/42.^[1a,2] ISMs were thus derived by linking the two hot segments IAPP(8–18) and IAPP(22–28) in native or N-methylated form to each other via different linkers, mostly tripeptide sequences consisting of identical amino acids; notably, these two segments are highly homologous to segments of the amyloid core of A β .^[3] High A β 40/42 anti-amyloidogenic activity was found for seven out of the 16 studied ISMs with six of them containing bulky hydrophobic/aromatic residues (e.g. LLL, III, FFF) in the linker tripeptide and one of them, termed R3-GI, the RRR tripeptide.

It has been recognized recently that liquid–liquid phase separation (LLPS) plays an important role for self-organization of membrane-less cellular organelles.^[4] In particular, proteins containing low-complexity sequences can form protein-rich droplets.^[5] Phase separation is the driving force for the formation of membrane-less cellular organelles such


[*] Z. Niu, M. Fleisch, A. C. Messias, R. Sarkar, M. Sattler, B. Reif
Helmholtz-Zentrum München (HMGU)
Deutsches Forschungszentrum für Gesundheit und Umwelt
Institute of Structural Biology
Ingolstädter Landstr. 1, 85764 Neuherberg (Germany)
E-mail: reif@tum.de


Z. Niu, E. Prade, A. Jussupow, Y. G. Mideksa, M. Fleisch, R. Sarkar,
M. Sattler, M. J. Feige, B. Reif
Technische Universität München (TUM)
Munich Center for Integrated Protein Science (CIPS-M) at the
Department of Chemistry
Lichtenbergstr. 4, 85747 Garching (Germany)
E. Malideli, K. Hille, L.-M. Yan, A. Kapurniotu
Technische Universität München (TUM)
TUM School of Life Sciences
Division of Peptide Biochemistry
Emil-Erlenmeyer-Forum 5
85354 Freising (Germany)
E-mail: akapurniotu@wzw.tum.de

A. Jussupow, Y. G. Mideksa, M. J. Feige, C. Camilloni
Technische Universität München (TUM)
Institute for Advanced Study
Lichtenbergstr. 2a, 85748 Garching (Germany)

C. Qian, D. C. Lamb
Ludwig-Maximilians-Universität, Munich
Department of Chemistry, Center for Integrated Protein Science
Munich (CIPSM), Nanosystems Initiative Munich (NIM) and Center
for Nanoscience (CeNS)
Butenandstr. 5, 81377 München (Germany)

C. Camilloni
Università degli Studi di Milano
Dipartimento di Bioscienze
Via Giovanni Celoria 26, 20133 Milano (Italy)

 Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/anie.201914559>.

 © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

as nucleoli, stress granules, P-bodies, and other cellular compartments.^[6] Similar to stress granules, hydrophobic small molecules undergo LLPS, adopt colloidal structures in aqueous environment,^[7] and recruit amyloidogenic proteins into their core in which amyloids adopt an altered structure that prevents amyloid neurotoxicity.^[8] The elevated local concentration facilitates interactions with the amyloid.

Herein, we show that R3-GI is highly dynamic, can adopt a β -like structure, and oligomerizes into colloid-like assemblies. Our results suggest that formation of such ISM assemblies provides a multivalent surface for interactions with A β 40, resulting in its sequestration into off-pathway non-toxic aggregates. The suggested mechanism provides a possible mechanistic scenario for the potent amyloid inhibitor function of ISMs.

Results

Our studies focused on the two ISMs R3-GI and K3-L3-K3-GI for the following reasons (Figure 1 A and Table S1 in the Supporting Information): 1) R3-GI was used in solution-state NMR studies as the intrinsically low solubility of all ISMs with hydrophobic linkers makes them unsuitable for solution-state NMR spectroscopy. 2) K3-L3-K3-GI was used in MAS solid-state NMR studies as it is a reasonably soluble and functional analogue (Figure S1) of the sparingly soluble but highly potent L3-GI (LLL in the linker), which shows the largest effects in terms of substrate interaction.^[1b] A third ISM, the non-inhibitor G3-GI containing the flexible GGG tripeptide as linker, was used as a control peptide.

ISM Self-Association and Exchange between Monomeric and Oligomeric States

Most of the ISMs self-associate with apparent binding affinities (app. K_d) in the low- to mid-nanomolar concentration range.^[1b] In the case of R3-GI, an app. K_d value of 77 nM was determined by titrating synthetic N-terminal fluorescently labeled peptide (Fluos-R3-GI) with R3-GI (Figure 1 A). The high oligomerization propensity of R3-GI was further confirmed by concentration-dependent CD studies (Figure S2D), chemical cross-linking (Figure 1 B), and dynamic light scattering (DLS; Figure 1 C). In addition, differential interference contrast (DIC) microscopy, fluorescence microscopy, and transmission electron microscopy showed that R3-GI aggregation resulted in granule-like, high-molecular-weight structures (Figure 1D–F). As expected, R3-GI assemblies within these structures have a significantly retarded translational diffusion coefficient in comparison to particles in isotropic solution (Figure 1 G). Next, we recorded solution-state NMR spectra of R3-GI at a concentration of 1.5 mM (Figure S2 A). At this concentration, peptide self-association should result in aggregates that are too large to be observable by solution-state NMR spectroscopy. Unexpectedly, high-intensity and high-resolution spectra were obtained that are characteristic for monomeric, random-coil peptides. The ^{13}C chemical shifts, which are

sensitive to secondary structure,^[9] yielded no indication for formation of α -helical or β -sheet secondary structure elements (Figure S2 C).

In order to resolve the apparent discrepancy between the NMR findings and the results of the other biophysical studies, we performed fluorescence recovery after photobleaching (FRAP) experiments (Figure 1 H). We found that the fluorescence of the granules recovered within seconds, indicating that peptides exchange between the peptide-dense phase and bulk solution. In addition, we conducted saturation transfer difference (STD) experiments for R3-GI (Figure 1 I). We observed very intense signals in this experiment, suggesting that R3-GI undergoes chemical exchange between a monomeric random-coil-like conformation and an aggregated state that is too large to be observable by solution-state NMR analysis. In contrast, a non-aggregating monomeric peptide used as a control yielded no STD signals. Notably, similar behavior has been observed previously for the Alzheimer's disease A β peptide, which has been shown to exchange between a soluble and an aggregated state.^[10] These findings are in agreement with DOSY experiments (Figure S2 E, F). We observed a smaller apparent diffusion coefficient that is consistent with R3-GI undergoing a transition between a monomeric and an aggregated state. Next, we quantified the amount of R3-GI in the aggregated state versus solution. For this purpose, we determined the intensities of the fluorescent granules with respect to background (Figure S3). We found a partitioning coefficient of R3-GI on the order of 2.9, which corresponds to an approximately threefold higher concentration in aggregates than in free solution.

NMR Structural Characterization of R3-GI

Subsequently, we recorded NOESY spectra to assign the resonances of R3-GI (Figure S2 A) and to determine the structure of the peptide. N-Methylation increases the population of a *cis* peptide conformer, and has been suggested to induce a turn structure similar to a proline.^[11] As expected, three sets of resonances are observed in the N-methyl region (residues N15–L20). We estimated the populations of the three conformers G17(*trans*)–I19(*trans*), G17(*cis*)–I19(*trans*), and G17(*trans*)–I19(*cis*) to be on the order of 64 %, 32 %, and 4 % (Figure S4). The G17(*cis*)–I19(*cis*) conformer is not sufficiently populated to be observable by NMR spectroscopy. Furthermore, we found different sets of resonances at the N-terminal half of the peptide (residues F8–H11; Figure S5), suggesting that N-methylation assists in turn formation of the monomeric peptide.

The STD NMR and FRAP experiments demonstrate that R3-GI exchanges between a monomeric and an oligomeric form. The experimental NOEs are thus transfer-NOEs^[12] containing contributions from the monomeric and the oligomeric state of the peptide. In fact, the observed NOEs are very intense, underlining the exchange contribution to the NOEs. Figure 2 A summarizes the experimental long-range ^1H , ^1H NOE connectivities for R3-GI. The observed contacts are indicative for a structure containing a loop. We investigated further the salt, temperature, and pH dependence for




Figure 1. R3-GI self-assembly. **A)** Top: sequences and abbreviations of IAPP and the investigated ISMs. “Hot segments” of the IAPP interaction surface with A β 40 are shown with black bold letters; residues in the IAPP loop and ISM linker regions are drawn in blue. The L3-GI solubilizing tag “KKK” is shown in italics. Bottom: fluorescence emission spectra of N-terminal fluorescein-labeled R3-GI (Fluos-R3-GI; 5 nM) alone and after titration with R3-GI at the indicated molar ratios (pH 7.4). On the right, the binding curve is shown. The estimated app. K_d value for R3-GI self-association is 77.1 (\pm 7.5) nM. Data are means (\pm SEM) from three binding curves. **B)** R3-GI oligomerization (500 μ M) studied by cross-linking with glutaraldehyde and NuPAGE. Lane 1: R3-GI without cross-linking; lanes 2–5: R3-GI cross-linked following incubation for 0 h (lane 2), 1 h (lane 3), 24 h (lane 4), and 48 h (lane 5). **C)** DLS studies of a 50 μ M R3-GI in 10 mM sodium phosphate buffer, pH 7.4 (containing 1% v/v HFIP). **D)** Differential interference contrast (DIC) micrograph of R3-GI (500 μ M). The peptide was imaged immediately after dissolution into 10 mM sodium phosphate buffer, pH 7.4 (containing 1% v/v HFIP) without filtration. Scale bar: 10 μ m. **E)** Microscopy image of Fluos-R3-GI in fluorescence mode. **F)** TEM image of R3-GI (500 μ M) in 10 mM sodium phosphate buffer, pH 7.4 (containing 1% v/v HFIP). Spherical assemblies were observed with diameters in the range of 200–400 nm. **G)** Fluorescence correlation spectroscopy (FCS) of a mixture of 454 μ M R3-GI and 454 nM Fluos-R3-GI showing that the translational diffusion inside the R3-GI granules is strongly retarded. **H)** Fluorescence recovery after photobleaching (FRAP) of a R3-GI granule. The fast recovery of the fluorescence intensity indicates that the majority of the peptide molecules are exchanging with the bulk solution within seconds. **I)** Saturation transfer difference (STD) NMR experiments of 1.25 mM R3-GI in 10 mM sodium phosphate buffer, pH 7.4 (containing 1% v/v HFIP and 10% v/v D₂O), showing that soluble, monomeric R3-GI undergoes exchange with a high-molecular-weight oligomeric R3-GI conformer. As a control, STD spectra of a 60 μ M solution of the peptide GVAE-PEQDCAVTSGE (M_r = 1.492 kDa) are shown. The control peptide is monomeric under the conditions employed in the experiment.

loop formation (Figures S6 and S7). Whereas the salt concentration did not have a significant impact on the intensity of the long-range cross-peaks in R3-GI, we found

that conditions of low pH significantly increased the intensity of the long-range cross-peaks. Similarly, we found that low temperatures increase the fraction of peptides adopting the




Figure 2. R3-GI NOESY experimental data and molecular modeling of the monomer. A) Long-distance NOE contacts plotted onto the R3-GI peptide sequence for conformers 1 and 2. B) Free energy diagram and structural ensembles for R3-GI.

turn-like structure (Figure S7). Interestingly, the (N7–I19)^[2] cross-peak intensity seems to correlate with the pK_a value of the histidine imidazole ring (Figure S8). We speculate that a lower pH and protonation of the histidine side chain is beneficial for loop formation in the aggregated state. At the same time, low pH has no influence on the population of the two conformers observed in the N-terminal half of the peptide (Figure S4). We observed long-range NOEs for both conformer 1 (G17(*trans*)–I19(*trans*)) and conformer 2 (G17(*cis*)–I19(*trans*); Figure 2A). By contrast, the non-inhibitor peptide G3-GI shows only weak long-range NOEs if any, suggesting that the loop-like structure is not adopted for G3-GI (Figure S9). These results are in good agreement with previous results and support the hypothesis underlying the design of the ISMs.^[1b]

Conformational ensembles representing the R3-GI conformers 1 and 2 were generated by metadynamic metainference^[13] using 221 and 35 inter-residue distance restraints for the first and the second conformer, respectively (Table S4 and Table S5). Metadynamic metainference represents an extension of the inferential structure determination approach introduced by Nilges and co-workers for heterogeneous systems.^[14] Using this method, an optimal coupling of simulations and equilibrium experiments allows one to determine the overall ensembles of structures that are compatible with the experimental data, in this case with the NOE-derived distances. The calculated ensembles for the two conformers are highly heterogeneous. In fact, a close inspec-

tion of the ensembles reveals significant differences. The G17(*trans*)–I19(*trans*) ensemble is characterized by an equilibrium between two populations. The first conformer is lacking any secondary structure and features a large radius of gyration (ca. 1.3 nm), while the second conformer is characterized by a loop forming a β -like structure involving residues N7–V10 to S21. The free energy for members of the two different populations is rather similar, suggesting that conformers of the two populations may interconvert on a fast timescale (microseconds or less). By contrast, the ensemble for the G17(*cis*)–I19(*trans*) conformer does not show any indication for a loop-like structure and is overall more compact with an average radius of gyration of 0.9 nm, reflecting the observed NOE between N7 and I19. The conformational ensembles suggest that the peptide is overall disordered in solution with some preference for a β -like structure, in particular for the G17(*trans*)–I19(*trans*) conformer.

The NOE intensities cannot easily be disentangled into contributions originating from the monomeric and the oligomeric state of the peptide. In order to probe peptide-peptide contacts in the oligomer, we prepared a mixed sample that contained 50% unlabeled (R3-GI) and 50% labeled peptide (R3-GI*); labeling scheme depicted in Figure 3). In the experiment, a magnetization filter element was applied during the first evolution period t_1 to remove magnetization of protons that are directly bound to ¹³C nuclei, following a double half-filter approach.^[15] After the NOESY mixing




Figure 3. Identification of intermolecular NOEs for R3-GI. A) Amino acid sequence and labeling scheme for R3-GI. Residues labeled in green are uniformly enriched with ^{13}C and ^{15}N . For the NMR experiment, labeled and non-labeled peptide was mixed in a 1:1 ratio. B) $^1\text{H}, ^{13}\text{C}$ correlation spectrum of R3-GI*. C) $^1\text{H}(\omega_1), ^1\text{H}(\omega_3)$ correlation spectrum extracted from the 3D NOESY experiment. During ω_1 , protons were selected that are directly bonded to ^{13}C , whereas ^{13}C -bound protons were filtered during ω_3 . In addition to trivial sequential connectivities (e.g., H11 β -V10 α) that appear only on one side of the diagonal, a number of symmetric cross-peaks (in red) were observed that are due to intermolecular interactions.

time, ^{13}C -bound protons were selected for detection. We found a number of sequential connectivities between labeled and non-labeled residues within one peptide (e.g., H11 β -V10 α). These cross-peaks are detected either above or below the diagonal, indicating that filtering of magnetization works in the intended way. In addition to these intramolecular sequential connectivities, we observed many correlations, which yielded a symmetric cross-peak both below and above the diagonal (A6 β -F8 β , A6 β -L9 β , F8 β -L9 β , L9 β -L9 δ). These correlations are due to intermolecular connectivities as they involve potentially labeled amino acids in both evolution periods.

In order to gain more structural insight, we performed MARTINI coarse-grain MD simulations (Figure 4).^[16] 54 monomers were solvated in a cubic box of 22.7 nm lateral length. The structure of the individual monomers was described by employing an elastic network centered around a representative G17(*trans*)-I19(*trans*) β -turn-like conformer. Interestingly, while the molecules self-assembled quickly on the timescale of the simulation (after 10 μs , the average oligomer size was stable between 24 and 30 monomers), the oligomers were overall very dynamic, showing a broad distribution of sizes and a significant fraction of free monomers (Figure 4A,B). Furthermore, monomers can exchange among oligomers on the microsecond timescale in agreement with STD experiments. The monomer-monomer interface is

well defined and characterized by few intermolecular interactions (Figure 4C). Arginine side chains are solvent-exposed (Figure 4D). Intermolecular interactions involve almost only amino acids 7–10. This is in agreement with the experimental intermolecular NOE contacts (Figure 3C), suggesting that the dynamic oligomer may represent well the macroscopic behavior of R3-GI at a small scale. As a control, five additional simulations were carried out to investigate the role of the linker sequence (Figure S11). First, the structure of the R3-GI monomer was relaxed by removing the elastic network around the β -like structure, which resulted in a more disordered peptide. Interestingly, the overall behavior of the system is robust with respect to this property. The resulting oligomer has similar dynamics and a similar intermolecular interface, while the average oligomer size is slightly decreased. Further control simulations with and without an elastic network were performed for G3-GI and for the peptide (SG)₁₀S with a supposedly totally flexible linker. For G3-GI and (SG)₁₀S, the oligomer dynamics disappears. Here, monomers self-assemble rapidly into 54-mers. Interestingly, differences can be observed for intermonomer interactions. While G3-GI retains specific intermolecular interactions very similar to R3-GI, the specific contacts are lost for the (SG)₁₀S peptide. The simulations indicate that both R3-GI and G3-GI can form oligomers with robust intermolecular interactions. The three arginine residues in the loop of R3-GI induce a




Figure 4. Coarse-grain MD simulations of R3-GI self-assembly. A) Average oligomer size during the simulation. The simulation was performed using a total of 54 monomers. A value of $N=54$ would imply that a single oligomer is formed encompassing all of the 54 simulated molecules; by contrast, a value of $N=1$ would indicate that all 54 molecules are monomeric in solution and no oligomers are formed. B) Distribution of the oligomer size over the simulation. C) Intermolecular contact probability map averaged over the simulation. D) Surface representation for a transient oligomeric state (blue for positively charged, red for negatively charged, green for polar, and white for hydrophobic side chains). The Figure shows an ensemble of monomers and oligomers of different sizes, together with their surface properties. Arginine side chains (in blue) are solvent-exposed. The inset shows a single oligomer enlarged, with arginine residues in ball-and-stick mode.

β -like structure that may determine the specific dynamic properties of the oligomers, which are essential for its inhibitory function.

Substrate Interactions

To investigate substrate interactions, we turned to the ISM K3-L3-K3-GI. Upon titration with A β 40, hetero-complexes precipitated quickly out of solution (Figure 5A, top). As a control, monomeric A β 40 was incubated with the non-inhibitor G3-GI, and no effects on A β 40 solubility were observed (Figure 5A, bottom). At the same time, the chemical shifts of A β 40 upon titration of the ISM K3-L3-K3-GI are not affected (Figure 5B). At a tenfold molar excess of the ISM peptide K3-L3-K3-GI with respect to A β 40, the $1D-^1H$ solution-state NMR spectrum is almost empty (Figure 5A, inset), indicating that the two peptides co-precipitated. By contrast, high intensities were observed for the control sample A β 40-G3-GI (Figure 5A, inset). Furthermore, fluorescence microscopy showed that K3-L3-K3-GI or R3-GI co-localize with A β 40 in the aggregates. By contrast, no co-localization with A β 40 was observed in the case of G3-GI (Figure 5C).

The K3-L3-K3-GI-induced A β 40 aggregates were analyzed by TEM and solid-state NMR spectroscopy. TEM indicates the presence of mainly amorphous aggregates while short A β 40 protofibril-like assemblies were also observed (Figure 6A,B). At first sight, the ISM-induced aggregates appear heterogeneous. However, solid-state NMR experiments yielded high-resolution spectra, indicating that the ISM-A β 40 co-assemblies are homogeneously structured (Figure 6C). In fact, the spectral resolution obtained for these aggregates is very similar to the resolution achieved for A β 40 fibrils that were obtained after several rounds of seeding.^[17] We performed chemical shift assignments to identify the residues of A β 40 that are part of the core of the ISM-induced aggregates (Table S6). Based on $^{13}C\alpha$ and $^{13}C\beta$ NMR chemical shifts, we predicted the β -strand secondary structure elements for K3-L3-K3-GI-induced A β 40 aggregates (Figure 6D). We found that the same residues as in an A β amyloid fibril are immobilized and involved in the β -sheet core.^[17] Furthermore, a comparison of the NMR secondary chemical shifts for the two preparations shows a high degree of similarity (Figure 6E), indicating that the fold of the two aggregates is rather related. In addition, we observed a TEDOR cross-peak involving the carboxyl group of residue Asp-23 and the ϵ -amino group of Lys-28 (Figure 6F), suggesting the formation of a salt bridge between the two




Figure 5. ISM–substrate interactions.

A) ^{15}N -filtered 1D- ^1H spectra of a $20\ \mu\text{M}$ sample of ^{15}N -labeled A β 40 in the absence (black) and presence of the ISM inhibitor K3-L3-K3-GI (top), and the non-inhibitor G3-GI (bottom). At a molar ratio of 1:1, only 9% of A β 40 remains in solution after addition of K3-L3-K3-GI, whereas the solubility of A β 40 is almost unaffected upon addition of G3-GI. At a tenfold excess of K3-L3-K3-GI, the resonances of A β 40 disappear quantitatively. At this molar excess, the intensities of A β 40 are reduced only to ca. 28% when G3-GI is titrated to A β 40. The inset shows the 1D- ^1H spectra of the respective samples. At a molar ratio of 1:10 for A β /inhibitor, the spectrum is dominated by the resonances of the inhibitor. The disappearance of all resonances in the case of K3-L3-K3-GI indicates that inhibitor and substrate co-precipitate. B) 2D ^1H - ^{15}N HSQCs of A β 40 incubated with K3-L3-K3-GI (red) at a molar ratio of 1:1. The A β 40 reference spectrum is represented in black. No A β 40 chemical shift changes were observed after addition of the ISM inhibitor. C) Comparison of the DIC and fluorescence microscopy images of R3-GI/A β 40, K3-L3-K3-GI/A β 40, and G3-GI/A β 40. Whereas Fluor-647-A β 40 incubated with either Fluos-R3-GI or Fluos-K3-L3-K3-GI yielded a perfect merge, Fluor-647-A β 40 incubated with Fluos-G3-GI yielded a distinct spatial distribution of red and green fluorescent spots, suggesting that G3-GI does not co-localize with A β 40. Scale: $10\ \mu\text{m}$.

residues. This interaction is a characteristic feature of all A β 40 fibril structures determined thus far,^[18] and confirms that also K3-L3-K3-GI-induced A β 40 aggregates adopt a

β -arch-like fold upon interaction with a substrate amyloid in the solid state. Even though the morphology of the K3-L3-K3-GI-induced A β 40 aggregates is rather different from that of




Figure 6. Structural characterization of K3-L3-K3-GI-induced A β 40 aggregates. A, B) TEM images of A β 40 in the absence (A) and presence (B) of an equimolar amount of K3-L3-K3-GI. Scale bar: 200 nm. C) 2D ^{13}C , ^{15}N MAS solid-state NMR correlation spectra obtained for K3-L3-K3-GI-induced A β 40 aggregates (red). To prepare the sample, a 20 μM solution of monomeric A β 40 was incubated with a 1.23-fold molar excess of K3-L3-K3-GI. For reference, the correlation spectrum obtained for A β 40 fibrils is shown in black. To prepare the A β 40 fibril sample, monomeric A β 40 was grown using 5% seeds, following the protocol described by Lopez and co-workers.^[17] (D) $\text{Ca}-\text{C}\beta$ chemical shift differences for K3-L3-K3-GI-induced A β 40 aggregates (top). TALOS+^[19]-predicted secondary structure propensity (bottom). E) Correlation of the NMR chemical shifts observed for K3-L3-K3-GI-induced A β aggregates and A β fibrils. On top and bottom, correlations for the absolute and secondary Ca chemical shifts are shown. Secondary Ca chemical shifts indicate differences from random-coil chemical shifts. The correlation coefficient is on the order of $R=0.954$ and $R=0.680$, respectively. The correlation coefficient is very high, indicating that the conformation in the two different preparations is surprisingly similar. F) 2D ^{13}C , ^{15}N TEDOR MAS solid-state NMR spectra for A β 40 fibrils (top) and K3-L3-K3-GI-induced A β 40 aggregates (bottom). Only the spectral region containing amino side chain nitrogen chemical shifts is shown. For both samples, a long-range correlation peak between $\text{N}\epsilon$ of Lys-28 and the carboxylic carbon atom of Asp-23 is observed, indicating that a salt bridge is formed in the K3-L3-K3-GI-induced A β 40 aggregates. The relative intensity of the long-range NH_3-COO^- cross peak appears to be larger in the K3-L3-K3-GI/A β 40 sample, indicating that this structure is presumably more compact.

A β 40 amyloid fibrils, we conclude that both complexes adopt a similar β -sheet/turn/ β -sheet molecular architecture. However, a more detailed structural analysis is necessary to characterize the exact structural features of ISM-induced A β aggregates.

Discussion

We have found that the ISM inhibitor R3-GI can adopt a β -like fold in solution. At the same time, we observed supramolecular, granule-like structures by DIC and fluorescence microscopy, which suggests that R3-GI may undergo LLPS. STD NMR and FRAP experiments implied that the peptide exchanges between a monomeric and a high-molecular-weight soluble aggregated state. MAS solid-state NMR experiments showed that the β -arch-like architecture of an A β 40 amyloid fibril with the characteristic salt bridge between Asp-23 and Lys-28 is preserved in the solid state in the amyloid-inhibitor complex. R3-GI peptides thus form highly dynamic assemblies that provide a suitable surface for sequestration of A β 40.

Conventional inhibitors, following the classical key-lock or induced-fit principle, target specific structural motifs, for example, a deep hydrophobic binding pocket.^[20] To be potent, these inhibitors have to be very specific with a high binding affinity. When the binding specificity is reduced, ligands can exploit multivalent interactions to yield increased avidity. Bacterial toxin inhibitors, for example, are based on multivalent scaffolds.^[21] Similarly, most protein-carbohydrate interactions are multivalent to compensate for their low affinities. Multivalency has been employed to trigger signal transduction by inducing receptor clustering,^[22] and to design amyloid A β inhibitors^[23] where small-molecule inhibitors have been covalently coupled to chaperones to increase their steric bulk. We suggest that R3-GI and related ISMs exploit multivalency by self-association. The correct spatial arrangement of side chains allows them to efficiently capture A β 40 and direct it into off-pathway non-toxic aggregates.^[24]

Figure 7 schematically illustrates different amyloid self-assembly inhibition mechanisms involving classical single-site binding, together with intervention strategies that employ colloid formation or the here suggested ISM-induced LLPS-like process. Single-site binding events are the classical paradigm for a drug-enzyme complex. Because of the low affinity and the lack of deep binding pockets, this class of inhibitors is not very effective for amyloids (Figure 7, top). Nevertheless, it has been shown that multi-ligand interactions of tramisprostate with monomeric A β 42 can prevent amyloid oligomer formation.^[25] Hydrophobic small molecules can form colloids that resemble protein liquid droplets in size.^[7]




Figure 7. Different mechanistic pathways of ligand binding to amyloidogenic proteins. Top: mono-valent ligands (e.g., small molecules) bind to a specific site in a particular peptide strand. Middle: in colloids, the local small-molecule concentration is increased, facilitating ligand binding. Amyloid peptides are recruited into the colloid. Bottom: the IAPP-derived ISM inhibitor R3-GI is suggested to self-assemble and recruit A β 40 into non-toxic aggregates. Circles and squares represent hydrophilic and hydrophobic side chains, respectively. The inner core of the ISM is shown in light blue to indicate its hydrophobic environment.

These small-molecule colloids are, however, unspecific inhibitors, as they interact promiscuously with hydrophobic regions of a protein and eventually induce protein unfolding. We have shown previously that NSAIDs (non-steroidal anti-inflammatory drugs) such as sulindac sulfide can bind into hydrophobic cavities of amyloid fibrils, and stabilize aggregates.^[8,26] The NSAID accelerates A β peptide aggregation by recruiting A β peptides into its colloidal core (Figure 7, center).

Our data suggest that ISMs may act via a similar mechanism: ISMs are active at very low concentrations and make use of multivalent interactions, which may dramatically increase avidity (Figure 7, bottom). Multivalent interactions between an inhibitor molecule and an amyloid fibril have been exploited by Wall and co-workers,^[27] who designed an α -helical peptide with a lysine basic side chain to interact with negatively charged residues exposed on the surface of amyloid structures. These inhibitors are used as imaging reagents and stabilize a fibrillar fold. In contrast, ISMs prevent amyloid formation and redirect A β 40 into an off-pathway aggregate that lacks cellular toxicity. Importantly, R3-GI self-assembly is likely required but not sufficient for its amyloid inhibitor function. In fact, macroscopic particles are observed in solution for both the non-inhibitor G3-GI and the inhibitor R3-GI in DIC experiments. However, only R3-GI yields long-range contacts in NOESY experiments, supporting the idea that the specific loop-containing structure of R3-GI identified here is essential for its potent inhibitory function.^[1b] Notably, A β 40 in solution exhibits a conformational preference for β -arch-like structures as well.^[28] Thus, R3-GI and related ISMs may exert their inhibitory function

by providing a structural template to which specific, amyloidogenic A β 40 conformers can adhere.

Conclusion

The highly potent inhibitor function of the ISMs renders them well suited templates for the development of anti-amyloid drugs.^[1b,24b] Our findings provide a molecular basis for understanding their function and should thus assist in the design of novel potent anti-amyloid drugs. In addition, they may contribute to elucidating the mechanism of previously reported self-assembling peptide inhibitors designed to mimic surfaces involved in self- or cross-amyloid interactions, for which the mode of action is thus far not understood.^[29]

Acknowledgements

We thank Dr. Sam Asami and Dr. Leonidas Emmanouilidis for stimulating discussions. We thank Dr. Karine Farbiarz for synthesis and preliminary studies on K3-L3-K3-GI, Dr. Anna Spanopoulou for preliminary DLS studies, and Dr. Erika Andreetto for helpful discussions. We thank Dr. Michaela Aichler and Gabriele Mettenleiter for technical assistance with the EM microscope. We thank the SFB 1035 for financial support (German Research Foundation DFG, Sonderforschungsbereich 1035, projects A11, B06, B07, B11). A.J., C.C., and M.J.F. acknowledge support of the Technische Universität München, Institute for Advanced Study through the German Excellence Initiative and the European Union Seventh Framework Programme under Grant Agreement No. 291763. D.C.L. acknowledges the support by the Ludwig-Maximilians-Universität München through the Center for NanoScience (CeNS) and the BioImaging Network (BIN). Z.N. is grateful for a PhD scholarship from the China Scholarship Council (CSC). Y.G.M. acknowledges funding of a DAAD PhD scholarship. We gratefully acknowledge the Gauss Centre for Supercomputing e.V. (www.gauss-centre.eu) for funding this project by providing computing time on the GCS supercomputer SuperMUC at the Leibniz Supercomputing Centre (LRZ, www.lrz.de). We are grateful to the Center for Integrated Protein Science Munich (CIPS-M) for financial support. We acknowledge support from the Helmholtz-Gemeinschaft.

Conflict of interest

All authors except for A.K., who is a coinventor in a patent application on ISMs reported in this work, declare no conflict of interest.

Keywords: amyloid formation · amyloid inhibitors · A β · solid-state NMR spectroscopy · peptides

How to cite: *Angew. Chem. Int. Ed.* **2020**, *59*, 5771–5781
Angew. Chem. **2020**, *132*, 5820–5830

- [1] a) E. Andreetto, L. M. Yan, M. Tatarek-Nossol, A. Velkova, R. Frank, A. Kapurniotu, *Angew. Chem. Int. Ed.* **2010**, *49*, 3081–3085; *Angew. Chem.* **2010**, *122*, 3146–3151; b) E. Andreetto, E. Malideli, L.-M. Yan, M. Kracklauer, K. Farbiarz, M. Tatarek-Nossol, G. Rammes, E. Prade, T. Neumüller, A. Caporale, A. Spanopoulou, M. Bakou, B. Reif, A. Kapurniotu, *Angew. Chem. Int. Ed.* **2015**, *54*, 13095–13100; *Angew. Chem.* **2015**, *127*, 13287–13292.
- [2] D. Eisenberg, M. Jucker, *Cell* **2012**, *148*, 1188–1203.
- [3] L.-M. Yan, A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu, *Angew. Chem. Int. Ed.* **2007**, *46*, 1246–1252; *Angew. Chem.* **2007**, *119*, 1268–1274.
- [4] D. M. Mitrea, R. W. Kriwacki, *Cell Commun. Signaling* **2016**, *14*, 1.
- [5] a) A. Molliex, J. Temirov, J. Lee, M. Coughlin, A. P. Kanagaraj, H. J. Kim, T. Mittag, J. P. Taylor, *Cell* **2015**, *163*, 123–133; b) Y. Lin, D. S. W. Protter, M. K. Rosen, R. Parker, *Mol. Cell* **2015**, *60*, 208–219; c) A. Patel, H. O. Lee, L. Jawerth, S. Maharana, M. Jahnel, M. Y. Hein, S. Stoykov, J. Mahamid, S. Saha, T. M. Franzmann, A. Pozniakovski, I. Poser, N. Maghelli, L. A. Royer, M. Weigert, E. W. Myers, S. Grill, D. Drechsel, A. A. Hyman, S. Alberti, *Cell* **2015**, *162*, 1066–1077.
- [6] a) C. P. Brangwynne, C. R. Eckmann, D. S. Courson, A. Rybarska, C. Hoegge, J. Gharakhani, F. Julicher, A. A. Hyman, *Science* **2009**, *324*, 1729–1732; b) C. P. Brangwynne, T. J. Mitchison, A. A. Hyman, *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 4334–4339.
- [7] B. Y. Feng, B. H. Toyama, H. Wille, D. W. Colby, S. R. Collins, B. C. H. May, S. B. Prusiner, J. Weissman, B. K. Shoichet, *Nat. Chem. Biol.* **2008**, *4*, 197–199.
- [8] E. Prade, C. Barucker, R. Sarkar, G. Althoff-Ospelt, J. M. Lopez del Amo, S. Hossain, Y. Zhong, G. Multhaup, B. Reif, *Biochemistry* **2016**, *55*, 1839–1849.
- [9] D. S. Wishart, B. D. Sykes, *J. Biomol. NMR* **1994**, *4*, 171–180.
- [10] a) S. Narayanan, B. Reif, *Biochemistry* **2005**, *44*, 1444–1452; b) N. L. Fawzi, J. F. Ying, D. A. Torchia, G. M. Clore, *J. Am. Chem. Soc.* **2010**, *132*, 9948–9951.
- [11] a) H. Weisshoff, T. Wieprecht, P. Henklein, C. Frommel, C. Antz, C. Mugge, *FEBS Lett.* **1996**, *387*, 201–207; b) B. Laufer, J. Chatterjee, A. O. Frank, H. Kessler, *J. Pept. Sci.* **2009**, *15*, 141–146.
- [12] F. Ni, *Prog. Nucl. Magn. Reson. Spectrosc.* **1994**, *26*, 517–606.
- [13] M. Bonomi, C. Camilloni, M. Vendruscolo, *Sci. Rep.* **2016**, *6*, 31232.
- [14] W. Rieping, M. Habeck, M. Nilges, *Science* **2005**, *309*, 303–306.
- [15] a) G. Wider, C. Weber, R. Traber, H. Widmer, K. Wuthrich, *J. Am. Chem. Soc.* **1990**, *112*, 9015–9016; b) M. Ikura, A. Bax, *J. Am. Chem. Soc.* **1992**, *114*, 2433–2440; c) J. Cavanagh, W. J. Fairbrother, A. G. Palmer, N. J. Skelton, *Protein NMR Spectroscopy: Principles and Practice*, Academic Press, San Diego, **1996**; d) M. Sattler, J. Schleucher, C. Griesinger, *Prog. Nucl. Magn. Reson. Spectrosc.* **1999**, *34*, 93–158.
- [16] S. J. Marrink, H. J. Risselada, S. Yefimov, D. P. Tieleman, A. H. de Vries, *J. Phys. Chem. B* **2007**, *111*, 7812–7824.
- [17] J. M. Lopez del Amo, M. Schmidt, U. Fink, M. Dasari, M. Fändrich, B. Reif, *Angew. Chem. Int. Ed.* **2012**, *51*, 6136–6139; *Angew. Chem.* **2012**, *124*, 6240–6243.
- [18] a) R. Tycko, *Q. Rev. Biophys.* **2006**, *39*, 1–55; b) A. K. Paravastu, R. D. Leapman, W.-M. Yau, R. Tycko, *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 18349–18354; c) J. X. Lu, W. Qiang, W. M. Yau, C. D. Schwieters, S. C. Meredith, R. Tycko, *Cell* **2013**, *154*, 1257–1268.
- [19] Y. Shen, F. Delaglio, G. Cornilescu, A. Bax, *J. Biomol. NMR* **2009**, *44*, 213–223.
- [20] D. E. Koshland, *Angew. Chem. Int. Ed. Engl.* **1994**, *33*, 2375–2378; *Angew. Chem.* **1994**, *106*, 2468–2470.

- [21] T. R. Branson, W. B. Turnbull, *Chem. Soc. Rev.* **2013**, *42*, 4613–4622.
- [22] L. L. Kiessling, J. E. Gestwicki, L. E. Strong, *Angew. Chem. Int. Ed.* **2006**, *45*, 2348–2368; *Angew. Chem.* **2006**, *118*, 2408–2429.
- [23] J. E. Gestwicki, G. R. Crabtree, I. A. Graef, *Science* **2004**, *306*, 865–869.
- [24] a) M. Bakou, K. Hille, M. Kracklauer, A. Spanopoulou, C. V. Frost, E. Malideli, L. M. Yan, A. Caporale, M. Zacharias, A. Kapurniotu, *J. Biol. Chem.* **2017**, *292*, 14587–14602; b) A. Spanopoulou, L. Heidrich, H. R. Chen, C. Frost, D. Hrle, E. Malideli, K. Hille, A. Grammatikopoulos, J. Bernhagen, M. Zacharias, G. Rammes, A. Kapurniotu, *Angew. Chem. Int. Ed.* **2018**, *57*, 14503–14508; *Angew. Chem.* **2018**, *130*, 14711–14716.
- [25] P. Kocis, M. Tolar, J. Yu, W. Sinko, S. Ray, K. Blennow, H. Fillit, J. A. Hey, *CNS Drugs* **2017**, *31*, 495–509.
- [26] E. Prade, H. J. Bittner, R. Sarkar, J. M. Lopez del Amo, G. Althoff-Ospelt, G. Multhaup, P. W. Hildebrand, B. Reif, *J. Biol. Chem.* **2015**, *290*, 28737–28745.
- [27] J. S. Wall, E. B. Martin, T. Richey, A. C. Stuckey, S. Macy, C. Wooliver, A. Williams, J. S. Foster, P. McWilliams-Koeppe, E. Uberbacher, X. L. Cheng, S. J. Kennel, *Molecules* **2015**, *20*, 7657–7682.
- [28] a) F. N. Newby, A. De Simone, M. Yagi-Utsumi, X. Salvatella, C. M. Dobson, M. Vendruscolo, *Biochemistry* **2015**, *54*, 6876–6886; b) D. Granata, F. Baftizadeh, J. Habchi, C. Galvagnion, A. De Simone, C. Camilloni, A. Laio, M. Vendruscolo, *Sci. Rep.* **2015**, *5*, 15449.
- [29] a) G. Yamin, P. Ruchala, D. B. Teplow, *Biochemistry* **2009**, *48*, 11329–11331; b) P. N. Cheng, C. Liu, M. L. Zhao, D. Eisenberg, J. S. Nowick, *Nat. Chem.* **2012**, *4*, 927–933; c) M. Richman, S. Wilk, M. Chemerovski, S. K. T. S. Warmlander, A. Wahlstrom, A. Graslund, S. Rahimipour, *J. Am. Chem. Soc.* **2013**, *135*, 3474–3484; d) K. M. Pate, B. J. Kim, E. V. Shusta, R. M. Murphy, *ChemMedChem* **2018**, *13*, 968–979.

Manuscript received: November 14, 2019

Revised manuscript received: December 13, 2019

Accepted manuscript online: December 21, 2019

Version of record online: January 28, 2020